Longwood Capital logo

Longwood Capital

Crunchbase
Pitchbook
Crunchbase

Deals on record

5

Common Fundraising Type

Equity

Be Bio logo
Be Bio

Engineered B Cell Medicines

Nextech logo
Takeda Ventures logo
RA Capital Management logo
Longwood Fund logo
Bristol Myers Squibb logo
Atlas Venture logo
Arch Venture Partners logo
Alta Partners logo

Be Biopharma is developing engineered B cell medicines to produce therapeutic proteins for treating conditions like Hemophilia B and Hypophosphatasia.

Series C
$92M
01/15/2025
Article
Evommune logo
Evommune

Biotechnology

RA Capital Management logo
Verition Fund Management logo
Symbiosis logo
RTW Investments logo
Sectoral Asset Management logo
Pivotal bioVenture Partners logo
NEXTBio Capital logo
Marshall Wace logo

Evommune, Inc. is a biotechnology company focused on developing treatments for chronic inflammatory diseases.

Series C
$115M
10/31/2024
Article
Be Bio logo
Be Bio

Engineered B Cell Medicines

Takeda Ventures logo
RA Capital Management logo
Longwood Fund logo
Bristol Myers Squibb logo
Atlas Venture logo
Arch Venture Partners logo
Alta Partners logo

Be Biopharma is developing engineered B cell medicines to produce therapeutic proteins for treating conditions like Hemophilia B and Hypophosphatasia.

Equity
$82M
10/22/2024
Article
Lassen Therapeutics logo
Lassen Therapeutics

Clinical-stage biotech

Longitude Capital logo
Longwood Capital logo
Frazier Life Sciences logo
Catalio Capital Management logo
BVF Partners logo
Alta Partners logo

Lassen Therapeutics is a clinical-stage biotech company developing novel treatments for fibro-inflammatory diseases and cancer, focusing on therapies targeting the IL-11 and IL-18 pathways.

Series B
$85M
12/19/2023
Article
Sitryx Therapeutics logo
Sitryx Therapeutics

Biopharmaceutical

GSK logo
SV Health Investors logo
Sofinnova Partners logo
Oxford Science Enterprises logo
Longwood Fund logo
Eli Lilly & Company logo

Sitryx Therapeutics is a biopharmaceutical company that develops disease-modifying therapeutics for chronic autoimmune and inflammatory diseases by targeting and regulating cell metabolism.

Equity
$39M
09/27/2023
Article